Jun 02, 2022 6:30am EDT Intensity Therapeutics' INT230-6 Demonstrates Increased Survival as Either Monotherapy or in Combination with Ipilimumab in Patients with Relapsed, Refractory, Metastatic Sarcomas
May 03, 2022 8:01am EDT Intensity Therapeutics Announces New Clinical Data in Solid Tumors for its Lead Asset, INT230-6, were Accepted for Two Poster Discussion Sessions and Three Poster Presentations at the Upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Dec 10, 2021 8:01am EST Intensity Therapeutics Reports Promising Early Efficacy Results Using INT230-6 as a Monotherapy or in Combination with Pembrolizumab in Metastatic Breast Cancer at the 2021 San Antonio Breast Cancer Symposium®
Nov 30, 2021 8:01am EST Intensity Therapeutics Announces New Clinical Data Presentation for its Lead Asset, INT230-6, in Breast Cancer, at the 2021 San Antonio Breast Cancer Symposium® in December
Nov 13, 2021 8:01am EST Intensity Therapeutics Reports Promising Overall Survival Results Using INT230-6 as a Monotherapy or in Combination with Pembrolizumab or Ipilimumab to Treat Solid Tumors, at The Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
Nov 12, 2021 8:01am EST Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising Overall Survival Results in Adult Subjects with Metastatic Sarcomas at the Connective Tissue Oncology Society (CTOS) 2021 Virtual Annual Meeting
Nov 03, 2021 8:01am EDT Intensity Therapeutics' Data on Lead Asset, INT230-6, Accepted for Presentation at Two Major Scientific Clinical Oncology Conferences in November
Jun 02, 2021 8:05am EDT Intensity Therapeutics’ INT230-6 Demonstrates Efficacy as Either Monotherapy or in Combination with Checkpoint Inhibitors in Patients with Relapsed, Refractory, Metastatic Solid Tumors
May 20, 2021 8:05am EDT Intensity Therapeutics Announces Two Abstracts to Be Presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
